Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. STKE, 9 October 2007
Vol. 2007, Issue 407, p. cm2
[DOI: 10.1126/stke.4072007cm2]

CONNECTIONS MAP OVERVIEWS

PI3K Class IB Pathway

Simon Andrews1, Len R. Stephens2*, and Phillip T. Hawkins2*

1Bioinformatics Group,
2Inositide Laboratory, The Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK.

Abstract: Class I phosphoinositide 3-kinases (PI3Ks) are well-established signal transduction enzymes that play an important role in the mechanisms by which a wide variety of cell surface receptors control several cellular functions, including cellular growth, division, survival, and movement. Class IB PI3K (also known as PI3K{gamma}) allows fast-acting, heterotrimeric GTP-binding protein–coupled receptors to access this pathway. Activation of class IB PI3K results in the rapid synthesis of phosphatidylinositol-3,4,5-trisphosphate [PI(3,4,5)P3] and its dephosphorylation product, PI(3,4)P2, in the plasma membrane. These two lipid messengers bind to multiple, pleckstrin homology (PH) domain–containing effectors, which together regulate a complex signaling web downstream of receptor activation. This pathway regulates the activity of protein kinases and small guanosine triphosphatases that control cellular movement, adhesion, contraction, and secretion. Most of the ligands that have been established to activate class IB PI3K are involved in coordinating the body’s response to injury and infection through the regulation of multiple cell types in the immune system and vascular lining. Mice lacking the catalytic subunit of class IB PI3K are remarkably resistant to the development of several inflammatory pathologies in mouse models of human inflammatory disease. These results suggest small molecule inhibitors of class IB PI3K may represent a novel class of therapeutic agents that may complement existing anti-inflammatory treatments.

*Corresponding authors. E-mail, phillip.hawkins{at}bbsrc.ac.uk (P.H.); len.stephens{at}bbsrc.ac.uk (L.S.)

Citation: S. Andrews, L. R. Stephens, P. T. Hawkins, PI3K Class IB Pathway. Sci. STKE 2007, cm2 (2007).

Read the Full Text



To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882